[Bronchoscopic Lung Volume Reduction for Severe Chronic Obstructive Lung Disease].

Area of Science:

• Pulmonology
• Interventional Pulmonology

Context:

• Bronchoscopic lung volume reduction (BLVR) has over a decade of global experience, with more than 25,000 procedures performed worldwide.
• BLVR is recognized with an Evidence A rating in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.
• In Japan, BLVR received insurance coverage approval in December 2023, marking the commencement of treatments at designated facilities.

Purpose:

• To introduce Bronchoscopic lung volume reduction (BLVR) as a novel treatment option for severe chronic obstructive pulmonary disease (COPD) in Japan.
• To highlight BLVR's role in bridging the gap between medical and surgical interventions for severe COPD patients.
• To emphasize the importance of precise patient selection using tools like the Chartis system for successful BLVR outcomes.

Summary:

• BLVR is a minimally invasive procedure for severe COPD patients experiencing persistent dyspnea despite optimal medical management.
• The procedure is particularly relevant for Japan's prevalent homogeneous emphysema cases.
• Successful patient selection, including collateral ventilation assessment via the Chartis system, is crucial for effective treatment.

Impact:

• BLVR is anticipated to improve key metrics such as FEV1.0 and six-minute walk distance in patients.
• The treatment holds the potential to enhance survival rates for individuals with severe COPD.
• BLVR aims to help patients escape the debilitating cycle of COPD, improve their quality of life, and reduce COPD-related mortality.